To confirm whether the difference in NF-κB signaling was present in MM, we determined p38 and p65 phosphorylation levels in myeloma cells treated with TNFSF13B, with or without Bortezomib, for 30 min. This evidence concerns the gene NFKB1 and plasma cell myeloma.